Global CAR-T Therapy in Haematological Malignancy Market Growth (Status and Outlook) 2020-2025


Jun, 2020 | Report ID: 141081 | 134 | Pharmaceuticals and Healthcare

COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and Latin America, life in these regions has been upended the way it had been in Asia earlier in the developing crisis. As the coronavirus pandemic has worsened, the entertainment industry has been upended along with most every other facet of life. As experts work toward a better understanding, the world shudders in fear of the unknown, a worry that has rocked global financial markets, leading to daily volatility in the U.S. stock markets.

According to this latest study, the 2020 growth of CAR-T Therapy in Haematological Malignancy will have significant change from previous year. By the most conservative estimates of global CAR-T Therapy in Haematological Malignancy market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. We give this scenario a XX% probability, where under the scenario the supply chain will start to recover and quarantines and travel bans will ease, over the Q2. Longer-term, the effect of COVID-19 will be felt throughout the year with some degree of harm done by the virus. Over the next five years the CAR-T Therapy in Haematological Malignancy market will register a XX% CAGR in terms of revenue, the global market size will reach US$ XX million by 2025.

This report presents a comprehensive overview, market shares, and growth opportunities of CAR-T Therapy in Haematological Malignancy market by product type, application, key manufacturers and key regions and countries.

This study specially analyses the impact of Covid-19 outbreak on the CAR-T Therapy in Haematological Malignancy, covering the supply chain analysis, impact assessment to the CAR-T Therapy in Haematological Malignancy market size growth rate in several scenarios, and the measures to be undertaken by CAR-T Therapy in Haematological Malignancy companies in response to the COVID-19 epidemic.

Segmentation by type: breakdown data from 2015 to 2020 in Section 2.3; and forecast to 2025 in section 10.7.

Allogeneic

Autologous

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2025 in section 10.8.

Hospitals

Cancer Research Centers

Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.

Celgene (Juno Therapeutics)

Bluebird Bio

Novartis

Pfizer

CARsgen Therapeutics

Gilead (Kite Pharma)

Sorrento Therapeutics

Autolus Therapeutics

Mustang Bio

Aurora BioPharma

Collectis

Celyad

Allogene Therapeutics

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

To study and analyze the global CAR-T Therapy in Haematological Malignancy market size by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.

To understand the structure of CAR-T Therapy in Haematological Malignancy market by identifying its various subsegments.

Focuses on the key global CAR-T Therapy in Haematological Malignancy players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the CAR-T Therapy in Haematological Malignancy with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the size of CAR-T Therapy in Haematological Malignancy submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.


Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Scope of the Report

1.1 Market Introduction

1.2 Research Objectives

1.3 Years Considered

1.4 Market Research Methodology

1.5 Economic Indicators

1.6 Currency Considered

1.7 What is the Impact of Covid-19 Outbreak On the CAR-T Therapy in Haematological Malignancy?

1.7.1 Optimistic Scenario: COVID-19 Is Contained by May or June, with Normalcy Returning to Global Operations Through the End of Q2.

1.7.2 Conservative Scenario: COVID-19 Remains Prevalent, with Continued Impacts Lasting Into Q4.

1.7.3 Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global CAR-T Therapy in Haematological Malignancy Market Size in 2020, by Scenario

1.7.4 Corporate Strategy the Manufacturers Should Be Thinking About Right Now

2 Executive Summary

2.1 World Market Overview

2.1.1 Global CAR-T Therapy in Haematological Malignancy Market Size 2015-2025

2.1.2 CAR-T Therapy in Haematological Malignancy Market Size CAGR by Region

2.2 CAR-T Therapy in Haematological Malignancy Segment by Type

2.2.1 Allogeneic

2.2.2 Allogeneic

2.3 CAR-T Therapy in Haematological Malignancy Market Size by Type

2.3.1 Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2015-2020)

2.3.2 Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Type (2015-2020)

2.4 CAR-T Therapy in Haematological Malignancy Segment by Application

2.4.1 Hospitals

2.4.2 Cancer Research Centers

2.4.3 Others

2.5 CAR-T Therapy in Haematological Malignancy Market Size by Application

2.5.1 Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2015-2020)

2.5.2 Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Application (2015-2020)

3 Global CAR-T Therapy in Haematological Malignancy by Players

3.1 Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Players

3.1.1 Global CAR-T Therapy in Haematological Malignancy Market Size by Players (2018-2020)

3.1.2 Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Players (2018-2020)

3.2 Global CAR-T Therapy in Haematological Malignancy Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 CAR-T Therapy in Haematological Malignancy by Regions

4.1 CAR-T Therapy in Haematological Malignancy Market Size by Regions

4.2 Americas CAR-T Therapy in Haematological Malignancy Market Size Growth

4.3 APAC CAR-T Therapy in Haematological Malignancy Market Size Growth

4.4 Europe CAR-T Therapy in Haematological Malignancy Market Size Growth

4.5 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Growth

5 Americas

5.1 Americas CAR-T Therapy in Haematological Malignancy Market Size by Countries

5.2 Americas CAR-T Therapy in Haematological Malignancy Market Size by Type

5.3 Americas CAR-T Therapy in Haematological Malignancy Market Size by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC CAR-T Therapy in Haematological Malignancy Market Size by Regions

6.2 APAC CAR-T Therapy in Haematological Malignancy Market Size by Type

6.3 APAC CAR-T Therapy in Haematological Malignancy Market Size by Application

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 Key Economic Indicators of Few APAC Regions

7 Europe

7.1 Europe CAR-T Therapy in Haematological Malignancy by Countries

7.2 Europe CAR-T Therapy in Haematological Malignancy Market Size by Type

7.3 Europe CAR-T Therapy in Haematological Malignancy Market Size by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

7.9 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

8.1 Middle East & Africa CAR-T Therapy in Haematological Malignancy by Countries

8.2 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type

8.3 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers and Impact

9.1.1 Growing Demand from Key Regions

9.1.2 Growing Demand from Key Applications and Potential Industries

9.2 Market Challenges and Impact

9.3 Market Trends

10 Global CAR-T Therapy in Haematological Malignancy Market Forecast

10.1 Global CAR-T Therapy in Haematological Malignancy Market Size Forecast (2021-2025)

10.2 Global CAR-T Therapy in Haematological Malignancy Forecast by Regions

10.2.1 Global CAR-T Therapy in Haematological Malignancy Forecast by Regions (2021-2025)

10.2.2 Americas Market Forecast

10.2.3 APAC Market Forecast

10.2.4 Europe Market Forecast

10.2.5 Middle East & Africa Market Forecast

10.3 Americas Forecast by Countries

10.3.1 United States Market Forecast

10.3.2 Canada Market Forecast

10.3.3 Mexico Market Forecast

10.3.4 Brazil Market Forecast

10.4 APAC Forecast by Countries

10.4.1 China Market Forecast

10.4.2 Japan Market Forecast

10.4.3 Korea Market Forecast

10.4.4 Southeast Asia Market Forecast

10.4.5 India Market Forecast

10.4.6 Australia Market Forecast

10.5 Europe Forecast by Countries

10.5.1 Germany Market Forecast

10.5.2 France Market Forecast

10.5.3 UK Market Forecast

10.5.4 Italy Market Forecast

10.5.5 Russia Market Forecast

10.5.6 Spain Market Forecast

10.6 Middle East & Africa Forecast by Countries

10.6.1 Egypt Market Forecast

10.6.2 South Africa Market Forecast

10.6.3 Israel Market Forecast

10.6.4 Turkey Market Forecast

10.6.5 GCC Countries Market Forecast

10.7 Global CAR-T Therapy in Haematological Malignancy Forecast by Type

10.8 Global CAR-T Therapy in Haematological Malignancy Forecast by Application

11 Key Players Analysis

11.1 Celgene (Juno Therapeutics)

11.1.1 Company Details

11.1.2 CAR-T Therapy in Haematological Malignancy Product Offered

11.1.3 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2020)

11.1.4 Main Business Overview

11.1.5 Celgene (Juno Therapeutics) News

11.2 Bluebird Bio

11.2.1 Company Details

11.2.2 CAR-T Therapy in Haematological Malignancy Product Offered

11.2.3 Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2020)

11.2.4 Main Business Overview

11.2.5 Bluebird Bio News

11.3 Novartis

11.3.1 Company Details

11.3.2 CAR-T Therapy in Haematological Malignancy Product Offered

11.3.3 Novartis CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2020)

11.3.4 Main Business Overview

11.3.5 Novartis News

11.4 Pfizer

11.4.1 Company Details

11.4.2 CAR-T Therapy in Haematological Malignancy Product Offered

11.4.3 Pfizer CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2020)

11.4.4 Main Business Overview

11.4.5 Pfizer News

11.5 CARsgen Therapeutics

11.5.1 Company Details

11.5.2 CAR-T Therapy in Haematological Malignancy Product Offered

11.5.3 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2020)

11.5.4 Main Business Overview

11.5.5 CARsgen Therapeutics News

11.6 Gilead (Kite Pharma)

11.6.1 Company Details

11.6.2 CAR-T Therapy in Haematological Malignancy Product Offered

11.6.3 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2020)

11.6.4 Main Business Overview

11.6.5 Gilead (Kite Pharma) News

11.7 Sorrento Therapeutics

11.7.1 Company Details

11.7.2 CAR-T Therapy in Haematological Malignancy Product Offered

11.7.3 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2020)

11.7.4 Main Business Overview

11.7.5 Sorrento Therapeutics News

11.8 Autolus Therapeutics

11.8.1 Company Details

11.8.2 CAR-T Therapy in Haematological Malignancy Product Offered

11.8.3 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2020)

11.8.4 Main Business Overview

11.8.5 Autolus Therapeutics News

11.9 Mustang Bio

11.9.1 Company Details

11.9.2 CAR-T Therapy in Haematological Malignancy Product Offered

11.9.3 Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2020)

11.9.4 Main Business Overview

11.9.5 Mustang Bio News

11.10 Aurora BioPharma

11.10.1 Company Details

11.10.2 CAR-T Therapy in Haematological Malignancy Product Offered

11.10.3 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2020)

11.10.4 Main Business Overview

11.10.5 Aurora BioPharma News

11.11 Collectis

11.12 Celyad

11.13 Allogene Therapeutics

12 Research Findings and Conclusion

List of Tables

Table 1. Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global CAR-T Therapy in Haematological Malignancy Market Size in 2020, by Scenario

Table 2. COVID-19: Measures to be Undertaken by CAR-T Therapy in Haematological Malignancy Companies

Table 3. Research Methodology

Table 4. Data Source

Table 5. CAR-T Therapy in Haematological Malignancy Market Size CAGR by Region 2015-2025 ($ Millions)

Table 6. Major Players of Allogeneic

Table 7. Major Players of Autologous

Table 8. CAR-T Therapy in Haematological Malignancy Market Size by Type (2014-2019) ($ Millions)

Table 9. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2015-2020)

Table 10. Global CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) ($ Millions)

Table 11. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2015-2020)

Table 12. Global CAR-T Therapy in Haematological Malignancy Revenue by Players (2018-2020) ($ Millions)

Table 13. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Players (2018-2020)

Table 14. Global CAR-T Therapy in Haematological Malignancy Key Players Head office and Products Offered

Table 15. CAR-T Therapy in Haematological Malignancy Concentration Ratio (CR3, CR5 and CR10) (2018-2020)

Table 16. New Products and Potential Entrants

Table 17. Mergers & Acquisitions, Expansion

Table 18. Global CAR-T Therapy in Haematological Malignancy Market Size by Regions 2015-2020 ($ Millions)

Table 19. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Regions 2015-2020

Table 20. Americas CAR-T Therapy in Haematological Malignancy Market Size by Countries (2015-2020) ($ Millions)

Table 21. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Countries (2015-2020)

Table 22. Americas CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) ($ Millions)

Table 23. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2015-2020)

Table 24. Americas CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) ($ Millions)

Table 25. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2015-2020)

Table 26. APAC CAR-T Therapy in Haematological Malignancy Market Size by Regions (2015-2020) ($ Millions)

Table 27. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Regions (2015-2020)

Table 28. APAC CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) ($ Millions)

Table 29. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2015-2020)

Table 30. APAC CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) ($ Millions)

Table 31. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2015-2020)

Table 32. Europe CAR-T Therapy in Haematological Malignancy Market Size by Countries (2015-2020) ($ Millions)

Table 33. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Countries (2015-2020)

Table 34. Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) ($ Millions)

Table 35. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2015-2020)

Table 36. Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) ($ Millions)

Table 37. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2015-2020)

Table 38. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Countries (2015-2020) ($ Millions)

Table 39. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Countries (2015-2020)

Table 40. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) ($ Millions)

Table 41. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2015-2020)

Table 42. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) ($ Millions)

Table 43. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2015-2020)

Table 44. Key and Potential Regions of CAR-T Therapy in Haematological Malignancy

Table 45. Key Application and Potential Industries of CAR-T Therapy in Haematological Malignancy

Table 46. Key Challenges of CAR-T Therapy in Haematological Malignancy

Table 47. Key Trends of CAR-T Therapy in Haematological Malignancy

Table 48. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Regions (2021-2025) ($ Millions)

Table 49. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share Forecast by Regions

Table 50. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Type (2021-2025) ($ Millions)

Table 51. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share Forecast by Type (2021-2025)

Table 52. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Application (2021-2025) ($ Millions)

Table 53. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share Forecast by Application (2021-2025)

Table 54. Celgene (Juno Therapeutics) Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors

Table 55. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product Offered

Table 56. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue and Gross Margin (2018-2020E)

Table 57. Celgene (Juno Therapeutics) Main Business

Table 58. Celgene (Juno Therapeutics) Latest Developments

Table 59. Bluebird Bio Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors

Table 60. Bluebird Bio CAR-T Therapy in Haematological Malignancy Product Offered

Table 61. Bluebird Bio Main Business

Table 62. Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue and Gross Margin (2018-2020E)

Table 63. Bluebird Bio Latest Developments

Table 64. Novartis Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors

Table 65. Novartis CAR-T Therapy in Haematological Malignancy Product Offered

Table 66. Novartis Main Business

Table 67. Novartis CAR-T Therapy in Haematological Malignancy Revenue and Gross Margin (2018-2020E)

Table 68. Novartis Latest Developments

Table 69. Pfizer Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors

Table 70. Pfizer CAR-T Therapy in Haematological Malignancy Product Offered

Table 71. Pfizer Main Business

Table 72. Pfizer CAR-T Therapy in Haematological Malignancy Revenue and Gross Margin (2018-2020E)

Table 73. Pfizer Latest Developments

Table 74. CARsgen Therapeutics Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors

Table 75. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered

Table 76. CARsgen Therapeutics Main Business

Table 77. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue and Gross Margin (2018-2020E)

Table 78. CARsgen Therapeutics Latest Developments

Table 79. Gilead (Kite Pharma) Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors

Table 80. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product Offered

Table 81. Gilead (Kite Pharma) Main Business

Table 82. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue and Gross Margin (2018-2020E)

Table 83. Gilead (Kite Pharma) Latest Developments

Table 84. Sorrento Therapeutics Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors

Table 85. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered

Table 86. Sorrento Therapeutics Main Business

Table 87. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue and Gross Margin (2018-2020E)

Table 88. Sorrento Therapeutics Latest Developments

Table 89. Autolus Therapeutics Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors

Table 90. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered

Table 91. Autolus Therapeutics Main Business

Table 92. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue and Gross Margin (2018-2020E)

Table 93. Autolus Therapeutics Latest Developments

Table 94. Mustang Bio Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors

Table 95. Mustang Bio CAR-T Therapy in Haematological Malignancy Product Offered

Table 96. Mustang Bio Main Business

Table 97. Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue and Gross Margin (2018-2020E)

Table 98. Mustang Bio Latest Developments

Table 99. Aurora BioPharma Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors

Table 100. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product Offered

Table 101. Aurora BioPharma Main Business

Table 102. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue and Gross Margin (2018-2020E)

Table 103. Aurora BioPharma Latest Developments

Table 104. Collectis Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors

Table 105. Celyad Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors

Table 106. Allogene Therapeutics Details, Company Total Revenue (in $ million), Head Office, CAR-T Therapy in Haematological Malignancy Major Market Areas and Its Competitors

List of Figures

Figure 1. CAR-T Therapy in Haematological Malignancy Report Years Considered

Figure 2. Market Research Methodology

Figure 3. Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate 2015-2025 ($ Millions)

Figure 4. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2015-2020)

Figure 5. Global Allogeneic Market Size Growth Rate

Figure 6. Global Autologous Market Size Growth Rate

Figure 7. CAR-T Therapy in Haematological Malignancy in Hospitals

Figure 8. Global CAR-T Therapy in Haematological Malignancy Market: Hospitals (2015-2020) ($ Millions)

Figure 9. CAR-T Therapy in Haematological Malignancy in Cancer Research Centers

Figure 10. Global CAR-T Therapy in Haematological Malignancy Market: Cancer Research Centers (2015-2020) ($ Millions)

Figure 11. CAR-T Therapy in Haematological Malignancy in Others

Figure 12. Global CAR-T Therapy in Haematological Malignancy Market: Others (2015-2020) ($ Millions)

Figure 13. Global Others YoY Growth ($ Millions)

Figure 14. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application in 2019

Figure 15. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Regions 2015-2020

Figure 16. Americas CAR-T Therapy in Haematological Malignancy Market Size 2015-2020 ($ Millions)

Figure 17. APAC CAR-T Therapy in Haematological Malignancy Market Size 2015-2020 ($ Millions)

Figure 18. Europe CAR-T Therapy in Haematological Malignancy Market Size 2015-2020 ($ Millions)

Figure 19. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size 2015-2020 ($ Millions)

Figure 20. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Countries in 2019

Figure 21. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type in 2019

Figure 22. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application in 2019

Figure 23. United States CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)

Figure 24. Canada CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)

Figure 25. Mexico CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)

Figure 26. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Regions in 2019

Figure 27. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type in 2019

Figure 28. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application in 2019

Figure 29. China CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)

Figure 30. Japan CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)

Figure 31. Korea CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)

Figure 32. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)

Figure 33. India CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)

Figure 34. Australia CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)

Figure 35. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Countries in 2019

Figure 36. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type in 2019

Figure 37. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application in 2019

Figure 38. Germany CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)

Figure 39. France CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)

Figure 40. UK CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)

Figure 41. Italy CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)

Figure 42. Russia CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)

Figure 43. Spain CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)

Figure 44. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Countries in 2019

Figure 45. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type in 2019

Figure 46. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application in 2019

Figure 47. Egypt CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)

Figure 48. South Africa CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)

Figure 49. Israel CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)

Figure 50. Turkey CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)

Figure 51. GCC Countries CAR-T Therapy in Haematological Malignancy Market Size Growth 2015-2020 ($ Millions)

Figure 52. Global CAR-T Therapy in Haematological Malignancy arket Size Forecast (2021-2025) ($ Millions)

Figure 53. Americas CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 54. APAC CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 55. Europe CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 56. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 57. United States CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 58. Canada CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 59. Mexico CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 60. Brazil CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 61. China CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 62. Japan CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 63. Korea CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 64. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 65. India CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 66. Australia CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 67. Germany CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 68. France CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 69. UK CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 70. Italy CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 71. Russia CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 72. Spain CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 73. Egypt CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 74. South Africa CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 75. Israel CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 76. Turkey CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Figure 77. GCC Countries CAR-T Therapy in Haematological Malignancy Market Size 2021-2025 ($ Millions)

Sample Request is not available